ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,26%
Bitcoin
66.740,01
2,30%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Addex Therapeutics Ltd (ADXN)

  7. Addex Therapeutics Ltd (ADXN) News

ADXN

Addex Therapeutics (ADXN)

Addex Therapeutics Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ADXN
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202407h00GlobeNewswire Inc.Addex to Present at Bio€quity Europe 2024NASDAQ:ADXNAddex Therapeutics Ltd
29/04/202407h00GlobeNewswire Inc.Addex Provides Update on ADX71149 Phase 2 Epilepsy StudyNASDAQ:ADXNAddex Therapeutics Ltd
19/04/202407h00GlobeNewswire Inc.Addex to Present at the Swiss Biotech Day 2024NASDAQ:ADXNAddex Therapeutics Ltd
18/04/202407h00GlobeNewswire Inc.Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ADXNAddex Therapeutics Ltd
11/04/202407h00GlobeNewswire Inc.Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024NASDAQ:ADXNAddex Therapeutics Ltd
03/04/202407h00GlobeNewswire Inc.Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological DisordersNASDAQ:ADXNAddex Therapeutics Ltd
14/03/202407h00GlobeNewswire Inc.Addex to Present at the Bio-Europe Spring 2024 ConferenceNASDAQ:ADXNAddex Therapeutics Ltd
31/01/202407h00GlobeNewswire Inc.Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.NASDAQ:ADXNAddex Therapeutics Ltd
30/01/202423h00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ADXNAddex Therapeutics Ltd
30/01/202422h58Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADXNAddex Therapeutics Ltd
09/01/202407h00GlobeNewswire Inc.Addex to Present at the Swiss Equities Baader ConferenceNASDAQ:ADXNAddex Therapeutics Ltd
05/01/202407h30GlobeNewswire Inc.Addex to Present at Biotech Showcase™ 2024NASDAQ:ADXNAddex Therapeutics Ltd
21/12/202312h00Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:ADXNAddex Therapeutics Ltd
20/12/202312h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADXNAddex Therapeutics Ltd
20/12/202307h00GlobeNewswire Inc.Addex Shareholders Approve All Resolutions at Extraordinary General MeetingNASDAQ:ADXNAddex Therapeutics Ltd
14/12/202312h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADXNAddex Therapeutics Ltd
14/12/202307h00GlobeNewswire Inc.Addex Creates Treasury SharesNASDAQ:ADXNAddex Therapeutics Ltd
08/12/202320h11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ADXNAddex Therapeutics Ltd
30/11/202322h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ADXNAddex Therapeutics Ltd
30/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADXNAddex Therapeutics Ltd
29/11/202322h00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ADXNAddex Therapeutics Ltd
29/11/202312h27Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ADXNAddex Therapeutics Ltd
29/11/202312h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADXNAddex Therapeutics Ltd
29/11/202307h00GlobeNewswire Inc.Addex Reports Q3 2023 Financial Results and Provides Corporate UpdateNASDAQ:ADXNAddex Therapeutics Ltd
28/11/202312h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADXNAddex Therapeutics Ltd
28/11/202307h00GlobeNewswire Inc.Addex Convenes Extraordinary General MeetingNASDAQ:ADXNAddex Therapeutics Ltd
23/11/202307h00GlobeNewswire Inc.Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023NASDAQ:ADXNAddex Therapeutics Ltd
14/11/202307h00GlobeNewswire Inc.Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of PatientsNASDAQ:ADXNAddex Therapeutics Ltd
08/11/202312h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADXNAddex Therapeutics Ltd
08/11/202307h00GlobeNewswire Inc.Addex Regains Nasdaq Listing ComplianceNASDAQ:ADXNAddex Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:ADXN

Kürzlich von Ihnen besucht

TSXV
VTX
Vertex Resource
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten